Our primary development activities are focused
around oral route. We also have products under
the development that utilizes sublingual and
intra-nasal routes.
Our development activities utilize our technology
platform for New Chemical Entities (NCE) or existing
drug molecules that can benefit from our technology.
Our current product portfolio consists of products
in Gastro Intestinal (GI), Cardiovascular (CV) and
Central Nervous System (CNS) area. We actively
license and/or develop drug candidates that are
synergistic with our expertise.
We work in a semi-virtual environment. We have
collaborative arrangements with noted scientists
and universities. While we conduct most research
work in our laboratory or at the university, Scale up
and commercial manufacturing is done at our
partner facilities, with active monitoring by Patrin
Pharma. Our partners are around the globe and
they follow the strictest cGMP and GMP guidelines.
They have been inspected by various regulatory
agencies around the globe.
copyright Patrin Pharma 2005-2009
around oral route. We also have products under
the development that utilizes sublingual and
intra-nasal routes.
Our development activities utilize our technology
platform for New Chemical Entities (NCE) or existing
drug molecules that can benefit from our technology.
Our current product portfolio consists of products
in Gastro Intestinal (GI), Cardiovascular (CV) and
Central Nervous System (CNS) area. We actively
license and/or develop drug candidates that are
synergistic with our expertise.
We work in a semi-virtual environment. We have
collaborative arrangements with noted scientists
and universities. While we conduct most research
work in our laboratory or at the university, Scale up
and commercial manufacturing is done at our
partner facilities, with active monitoring by Patrin
Pharma. Our partners are around the globe and
they follow the strictest cGMP and GMP guidelines.
They have been inspected by various regulatory
agencies around the globe.
copyright Patrin Pharma 2005-2009
STRATEGY
 |
| |
 |
| |
 |
| |
 |
| |
 |
